Replicel Newsletter March 2019
March 5, 2019 /
Replicel has shared a newsletter today, March 5, 2019, addressing several facets of the company’s progress and product development. The big question for many people lately has been an update on RCH-01/Shiseido, this topic is briefly addressed in the newsletter.
Replicel states that “With the clinical study of RCH-01 now successfully completed in Japan, RepliCel expects Shiseido to declare its near-term plans for RCH-01.” This is interesting, and though not definitive, it states that in all likelihood we should be hearing some official news from Shiseido shortly. The important milestone is that they have completed their trial of RCH-01 which has been in progress since 2016.
It alludes to Shiseido wanting to terminate their agreement with Replicel regarding RCH-01. That’s a bit worrisome.
Hi follicle,
Thank you for sharing the Replicel statement. Now we know that the shiseido trial is been compleated succesfuly (whatever this means). You may have more information from Replicel C.E.O. Lee B. question is: Do you know whene we can expect to have any statment from shiseido regarding RCH-01?
Regards,
Piotr
Can we expect rch01 to be commercially in 2019 across asia at least?
My understanding is that Shiseido’s dispute with Replicel involves Replicel not completing their own Phase 2 trials of RCH-01 in Germany, as per the agreement between the two parties.
As such Shiseido now claim they are not bound by the agreement and do not have to share either their results, or any future revenues, with Replicel.
(Replicel dispute this by saying the agreement didn’t stipulate “when” they would conduct the German trials, just that they would).
Meanwhile Replicel’s joint research with the University of British Columbia (which the shareholder update states stage 1 of which “has successfully completed (details to be announced shortly)” – involved them seeking to clarify what differences existed in the hair follicle gene expression of subjects who had a strong hair growth response in their earlier RCH-01 phase I/IIa clinical trials and the subjects who had a reduced hair growth response.
Presumably if they can isolate what particular gene / protein expressions yield better treatment responses this might bring Shiseido back to the table – as they would otherwise be limited to using only the earlier technology covered in their agreement with Replicel.
How much all of this dispute is brinksmanship and how much is genuine is difficult to discern. Either way it will be interesting to see how it all pans out once both the results from the University of British Columbia joint study and Shiseido’s study are announced.
“If they can isolate what particular gene / protein expressions yield better treatment responses this might bring Shiseido back to the table”.
If the trials beeing compleated succesfully why do we need more improvements? Is this meanse that the treatment may not work for everybody even afrer 5 years of trials?
If they will isolate the particular gene/protein do thay have to start the clinincal trials (ad least for 1 year) again for the approvals or not?
Kind regeards,
Piotr
Doesn’t say that.
Tacobell… Where does it allude to that?
Where does it say that? I didn’t gather that from reading it.
Admin, any news regarding korea CM3 ? Q1 2019 is coming to an end soon
Admin,thanks for your hard work!
Do you know if there will be speakers from Shiseido at the World congress for hair restoration at Barcelona?
Thanks in advance!
Beautiful! Hopefully this brings us one step closer to a commercial release.
Any news about CM3?
There is some update!!
https://royalsocietypublishing.org/doi/10.1098/rsob.190010